Annual EBIT
-$309.33 M
+$55.45 M+15.20%
December 31, 2024
Summary
- As of February 24, 2025, TVTX annual earnings before interest & taxes is -$309.33 million, with the most recent change of +$55.45 million (+15.20%) on December 31, 2024.
- During the last 3 years, TVTX annual EBIT has fallen by -$112.13 million (-56.86%).
- TVTX annual EBIT is now -373.22% below its all-time high of $113.22 million, reached on December 31, 2015.
Performance
TVTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$57.52 M
-$5.46 M-10.50%
December 1, 2024
Summary
- As of February 24, 2025, TVTX quarterly earnings before interest & taxes is -$57.52 million, with the most recent change of -$5.46 million (-10.50%) on December 1, 2024.
- Over the past year, TVTX quarterly EBIT has increased by +$28.18 million (+32.88%).
- TVTX quarterly EBIT is now -139.66% below its all-time high of $145.03 million, reached on September 30, 2015.
Performance
TVTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$309.33 M
+$28.18 M+8.35%
December 1, 2024
Summary
- As of February 24, 2025, TVTX TTM earnings before interest & taxes is -$309.33 million, with the most recent change of +$28.18 million (+8.35%) on December 1, 2024.
- Over the past year, TVTX TTM EBIT has increased by +$55.45 million (+15.20%).
- TVTX TTM EBIT is now -346.22% below its all-time high of $125.63 million, reached on September 30, 2015.
Performance
TVTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TVTX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.2% | +32.9% | +15.2% |
| 3 y3 years | -56.9% | +32.9% | +15.2% |
| 5 y5 years | -142.4% | +32.9% | +15.2% |
TVTX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -56.9% | +15.2% | -10.5% | +56.7% | -56.9% | +23.4% |
| 5 y | 5-year | -142.4% | +15.2% | -333.1% | +56.7% | -296.4% | +23.4% |
| alltime | all time | -373.2% | +15.2% | -139.7% | +56.7% | -346.2% | +23.4% |
Travere Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$309.33 M(-15.2%) | - | - |
| Dec 2024 | - | -$57.52 M(+10.5%) | -$309.33 M(-8.4%) |
| Sep 2024 | - | -$52.06 M(-22.0%) | -$337.51 M(-9.2%) |
| Jun 2024 | - | -$66.78 M(-49.8%) | -$371.86 M(-8.0%) |
| Mar 2024 | - | -$132.97 M(+55.1%) | -$404.11 M(+10.8%) |
| Dec 2023 | -$364.78 M(+13.9%) | -$85.71 M(-0.8%) | -$364.77 M(+0.8%) |
| Sep 2023 | - | -$86.41 M(-12.7%) | -$361.78 M(+1.5%) |
| Jun 2023 | - | -$99.02 M(+5.8%) | -$356.46 M(+10.9%) |
| Mar 2023 | - | -$93.64 M(+13.2%) | -$321.45 M(+6.7%) |
| Dec 2022 | -$320.14 M(+62.3%) | -$82.72 M(+2.0%) | -$301.21 M(-0.5%) |
| Sep 2022 | - | -$81.09 M(+26.7%) | -$302.66 M(+20.0%) |
| Jun 2022 | - | -$64.01 M(-12.8%) | -$252.27 M(+13.4%) |
| Mar 2022 | - | -$73.40 M(-12.8%) | -$222.37 M(+12.8%) |
| Dec 2021 | -$197.20 M(+16.2%) | -$84.16 M(+174.2%) | -$197.20 M(-14.4%) |
| Sep 2021 | - | -$30.70 M(-10.0%) | -$230.37 M(+6.0%) |
| Jun 2021 | - | -$34.11 M(-29.3%) | -$217.43 M(+6.2%) |
| Mar 2021 | - | -$48.23 M(-58.9%) | -$204.69 M(+20.6%) |
| Dec 2020 | -$169.74 M(+33.0%) | -$117.33 M(+560.7%) | -$169.74 M(+117.5%) |
| Sep 2020 | - | -$17.76 M(-16.9%) | -$78.04 M(-15.9%) |
| Jun 2020 | - | -$21.37 M(+60.9%) | -$92.75 M(-11.8%) |
| Mar 2020 | - | -$13.28 M(-48.2%) | -$105.19 M(-17.6%) |
| Dec 2019 | -$127.62 M(+38.6%) | -$25.63 M(-21.1%) | -$127.62 M(+22.1%) |
| Sep 2019 | - | -$32.47 M(-4.0%) | -$104.48 M(-15.5%) |
| Jun 2019 | - | -$33.81 M(-5.3%) | -$123.59 M(+11.5%) |
| Mar 2019 | - | -$35.71 M(+1332.5%) | -$110.88 M(+20.3%) |
| Dec 2018 | -$92.06 M(+70.7%) | -$2.49 M(-95.2%) | -$92.16 M(-7.5%) |
| Sep 2018 | - | -$51.57 M(+144.3%) | -$99.60 M(+50.0%) |
| Jun 2018 | - | -$21.11 M(+24.2%) | -$66.39 M(+11.1%) |
| Mar 2018 | - | -$16.99 M(+71.1%) | -$59.78 M(+7.1%) |
| Dec 2017 | -$53.94 M | -$9.93 M(-45.9%) | -$55.81 M(+3.3%) |
| Sep 2017 | - | -$18.36 M(+26.6%) | -$54.04 M(-18.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$14.50 M(+11.3%) | -$66.03 M(-8.5%) |
| Mar 2017 | - | -$13.02 M(+59.5%) | -$72.18 M(+36.6%) |
| Dec 2016 | -$52.85 M(-146.7%) | -$8.16 M(-73.1%) | -$52.85 M(-7.8%) |
| Sep 2016 | - | -$30.35 M(+47.0%) | -$57.35 M(-148.6%) |
| Jun 2016 | - | -$20.65 M(-427.3%) | $118.03 M(+1.7%) |
| Mar 2016 | - | $6.31 M(-149.8%) | $116.09 M(+2.5%) |
| Dec 2015 | $113.22 M(-241.9%) | -$12.66 M(-108.7%) | $113.22 M(-9.9%) |
| Sep 2015 | - | $145.03 M(-742.0%) | $125.63 M(-461.5%) |
| Jun 2015 | - | -$22.59 M(-758.2%) | -$34.75 M(+4829.6%) |
| Mar 2015 | - | $3.43 M(-1500.8%) | -$705.00 K(-97.3%) |
| Dec 2014 | -$79.81 M(+222.2%) | -$245.00 K(-98.4%) | -$26.20 M(-12.9%) |
| Sep 2014 | - | -$15.35 M(-234.0%) | -$30.08 M(+51.3%) |
| Jun 2014 | - | $11.46 M(-151.9%) | -$19.88 M(-45.4%) |
| Mar 2014 | - | -$22.06 M(+434.8%) | -$36.44 M(+124.0%) |
| Dec 2013 | -$24.77 M(-18.1%) | -$4.13 M(-20.0%) | -$16.27 M(+33.9%) |
| Sep 2013 | - | -$5.15 M(+1.1%) | -$12.14 M(+73.7%) |
| Jun 2013 | - | -$5.10 M(+170.5%) | -$6.99 M(+269.0%) |
| Mar 2013 | - | -$1.89 M(>+9900.0%) | -$1.89 M(>+9900.0%) |
| Dec 2012 | -$30.26 M(>+9900.0%) | - | - |
| Nov 2012 | - | -$3200.00(+6.7%) | -$13.00 K(+1.6%) |
| Aug 2012 | - | -$3000.00(0.0%) | -$12.80 K(0.0%) |
| May 2012 | - | -$3000.00(-21.1%) | -$12.80 K(0.0%) |
| Feb 2012 | - | -$3800.00(+26.7%) | -$12.80 K(+1.6%) |
| Feb 2012 | -$12.80 K(+0.8%) | - | - |
| Nov 2011 | - | -$3000.00(0.0%) | -$12.60 K(-0.8%) |
| Aug 2011 | - | -$3000.00(0.0%) | -$12.70 K(-22.1%) |
| May 2011 | - | -$3000.00(-16.7%) | -$16.30 K(-18.1%) |
| Feb 2011 | -$12.70 K | -$3600.00(+16.1%) | -$19.90 K(+22.1%) |
| Nov 2010 | - | -$3100.00(-53.0%) | -$16.30 K(+23.5%) |
| Aug 2010 | - | -$6600.00(0.0%) | -$13.20 K(+100.0%) |
| May 2010 | - | -$6600.00 | -$6600.00 |
FAQ
- What is Travere Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Travere Therapeutics?
- What is Travere Therapeutics annual EBIT year-on-year change?
- What is Travere Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Travere Therapeutics?
- What is Travere Therapeutics quarterly EBIT year-on-year change?
- What is Travere Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Travere Therapeutics?
- What is Travere Therapeutics TTM EBIT year-on-year change?
What is Travere Therapeutics annual earnings before interest & taxes?
The current annual EBIT of TVTX is -$309.33 M
What is the all time high annual EBIT for Travere Therapeutics?
Travere Therapeutics all-time high annual earnings before interest & taxes is $113.22 M
What is Travere Therapeutics annual EBIT year-on-year change?
Over the past year, TVTX annual earnings before interest & taxes has changed by +$55.45 M (+15.20%)
What is Travere Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of TVTX is -$57.52 M
What is the all time high quarterly EBIT for Travere Therapeutics?
Travere Therapeutics all-time high quarterly earnings before interest & taxes is $145.03 M
What is Travere Therapeutics quarterly EBIT year-on-year change?
Over the past year, TVTX quarterly earnings before interest & taxes has changed by +$28.18 M (+32.88%)
What is Travere Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of TVTX is -$309.33 M
What is the all time high TTM EBIT for Travere Therapeutics?
Travere Therapeutics all-time high TTM earnings before interest & taxes is $125.63 M
What is Travere Therapeutics TTM EBIT year-on-year change?
Over the past year, TVTX TTM earnings before interest & taxes has changed by +$55.45 M (+15.20%)